Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:4

Sadržaj

članak: 1 od 4  
Back povratak na rezultate
2011, vol. 68, br. 1, str. 28-34
Primena eritrocita kod onkoloških bolesnika lečenih radio- i hemioterapijom
Zavod za transfuziju krvi, Niš

e-adresaztknis@medianis.net
Sažetak
Uvod/Cilj. Anemija je čest poremećaj kod bolesnika sa malignitetom. Ona znatno redukuje kvalitet života tih bolesnika, zbog čega zahteva ranu dijagnozu i adekvatno lečenje. Cilj ove studije bio je da se kod onkoloških bolesnika prikaže i analizira lečenje anemije primenom transfuzija eritrocita, proceni lečenje transfuzijom eritrocita u zavisnosti od koncentracije hemoglobina, kao i uticaj terapije za malignitet na stepen anemije i potrošnju eritrocita. Metode. Podaci o primeni transfuzije eritrocita u Klinici za onkologiju Kliničkog centra u Nišu u periodu od 1.1.2008. do 31.12.2008 godine retrospektivno su prikupljeni i analizirani. Rezultati. Kod svih bolesnika sa malignitetom poštovan je princip komponentne transfuzijske terapije. U periodu praćenja 735 bolesnika primilo je transfuziju 1 006 jedinica eritrocita (deplazmatisani, resuspendovani, isprani, filtrirani eritrociti). Prosečna potrošnja eritrocita po onkološkom bolesniku koji je primao transfuziju iznosila je 1,37 jedinica. Indikovanje transfuzije eritrocita bilo je adekvatno (87,60% bolesnika dobilo je transfuziju eritrocita pri Hb < 80 g/L). Tokom lečenja radio- i hemiotrapijom došlo je do sniženja vrednosti hematoloških parametara, pri čemu su bolesnici ispitivane grupe bili zavisni od primene transfuzije krvi i nastavak njihove radio- i hemioterapije bio je uslovljen primenom transfuzije eritrocita. Statistički značajnije smanjenje koncentracije hemoglobina registrovano je kod bolesnika koji su lečeni samo zračnom terapijom, te su ovi bolesnici bili, ujedno, i najveći potrošači eritrocita. Registrovana su dva bolesnika koji su najverovatnije imali febrilnu nehemolitičku transfuzijsku reakciju, dok se kod 0,68% bolesnika razvila posttransfuzijska aloimunizacija. Zaključak. Primena eritrocita kod onkoloških bolesnika u saglasnosti je sa savremenim trendovima i preporukama iz kliničkih vodiča. U cilju obezbeđenja primene bezbedne krvi neophodno je stalno praćenje najnovijih saznanja i stavova o kliničkoj primeni komponenata krvi.
Reference
Aapro, M., Spivak, J.L. (2009) Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist, 14(Suppl 1), str. 6-15
Alter, H.J., Klein, H.G. (2008) The hazards of blood transfusion in historical perspective. Blood, 112(7): 2617
Balint, B., Paunović, D., Stanojković, Z. (2004) Hemotherapy for patients with hemostatic disorders. u: Balint B. [ur.] Transfusiology, Beograd: Zavod za udžbenike i nastavna sredstva, str. 331-8
Barrett-Lee, P.J., Ludwig, H., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P.A., i dr. (2006) Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European Cancer Anaemia Survey. Oncology, 70(1): 34-48
Besarab, A., Hörl, W.H., Silverberg, D. (2009) Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist, 14(Suppl 1), str. 22-33
Beutler, E., Waalen, J. (2006) The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration. Blood, vol. 107.No 5, str. 1747-1750
Birgegård, G., Gascón, P., Ludwig, H. (2006) Evaluation of anaemia in patients with multiple myeloma and lymphoma: Findings of the European Cancer Anaemia Survey. European Journal of Haematology, 77(5): 378-386
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M., Weingart, O., Kluge, S., Piper, M., Rades, D., i dr. (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet, 373(9674): 1532-42
Cella, D. (2006) Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology, Williston Park, 20(8 Suppl 6): 25-8
Clarke, H., Pallister, C.J. (2005) The impact of anaemia on outcome in cancer. Clin Lab Haematol, 27(1): 1-13
Council of Europe (2008) Guide to the preparation, use and quality assurance of blood components. European Directorate for the Quality of medicines, Recommendations No. R(95)15. 14th ed
Drüeke, T.B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I.C., Tsakiris, D., Burger, H., Scherhag, A. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England journal of medicine, 355(20): 2071-84
Grgičević, D. (2006) Transfusion medicine in clinical practice. Zagreb: Medicinska naklada, in Croatian
Harrison, L., Blackwell, K. (2004) Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist, 9 Suppl 5 31-40
Institute for Mental Health (2005) National Guide: Erythrocytes transfusion in the treatment of anemia. Belgrade
Littlewood, T., Mandelli, F. (2002) The effects of anemia in hematologic malignancies: More than a symptom. Semin Oncol, 29(3 Suppl 8): 40-4
Luban, N.L. (2005) Transfusion safety: Where are we today?. Annals of the New York Academy of Sciences, 1054 (1): 325
Ministry of health of the Republic of Serbia (2005) National Guide: Administration of blood components and transfusion reactions. Belgrade: Ministry of Helath
National Comprehensive Cancer Network (NCCN) (2007) Cancer-and treatment-related anemia: Practice guidelines in oncology. Oncology, Williston Park, V. 2
Solheim, B.G., Wesenberg, F. (2001) Rational use of blood products. Eur J Cancer, 37(18): 2421-5; di
Spivak, J.L., Gascon, P., Ludwig, H. (2009) Anemia management in oncology and hematology. Oncologist, 14(suppl 1), str. 43-56
Spivak, J.L. (2005) The anaemia of cancer: Death by a thousand cuts. Nat Rev Cancer, 5(7): 543-55
Tchekmedyian, S.N. (2002) Anemia in cancer patients: Significance, epidemiology, and current therapy. Oncology, Williston Park, 16(9 Suppl 10): 17-24
Thomas, G., Ali, S., Hoebers, F.J.P., Darcy, K.M., Rodgers, W.H., Patel, M., Abulafia, O., Lucci, J.A., Begg, A.C. (2008) Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecologic oncology, 108(2): 317-25
Vamvakas, E.C., Blajchman, M.A. (2009) Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood, 113(15): 3406-17
Vaupel, P. (2008) Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. Oncologist, 13(Suppl 3), str. 21-6
Walther-Wenke, G. (2008) Incidence of bacterial transmission and transfusion reactions by blood components. Clinical chemistry and laboratory medicine, 46(7): 919-25
Waltzman, R.J., Gerardo, C. (2005) Anemia fatigue and quality of life. Oncology, Special Edition, 8, str. 51-55
Yazer, M.H., Podlosky, L., Clarke, G., Nahirniak, S.M. (2004) The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion, 44(1): 10-5
 

O članku

jezik rada: srpski
vrsta rada: originalan članak
DOI: 10.2298/VSP1101028A
objavljen u SCIndeksu: 18.01.2011.
metod recenzije: dvostruko anoniman